CD19 CAR-T cells + CD22 CAR-T cells

CD19 CAR-T cells + CD22 CAR-T cells is a combination cell therapy in which patient or donor-derived T lymphocytes are genetically engineered to express chimeric antigen receptors (CARs) targeting both the B-cell surface antigens CD19 and CD22. This dual-targeting approach is designed to treat relapsed or refractory B-cell malignancies, particularly acute lymphoblastic leukemia (ALL), by reducing the risk of antigen-negative relapse—a common mechanism of resistance seen with single-antigen targeted therapies. The product can be generated by cotransducing T-cells with separate vectors encoding anti-CD19 and anti-CD22 CARs, resulting in a mixed population capable of recognizing either or both antigens on malignant B-cells. Early-phase clinical trials have demonstrated high rates of measurable residual disease (MRD)-negative complete remission and favorable safety profiles compared to single-antigen approaches, with reduced incidence of severe cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). However, this therapy remains investigational; it has not yet received regulatory approval for any indication[1][2][3][5][6].

Other names

CD19/CD22 CAR T-cell therapydual-targeted CD19/CD22 CAR T-cell therapycotransduced CD19 and CD22 CAR T cells